Gene delivery agents
Inventors
Talukder, Poulami • Varghese, Maria • SONG, Heliang • Ivanowsky, Nathan
Assignees
Interested in licensing this patent?
MTEC can help explore whether this patent might be available for licensing for your application.
Abstract
Nanoparticle compositions for delivery of nucleic acids to subjects including aminoalkyl branched lipid-like molecules as carriers, and therapeutic or immunogenic nucleic acid agents enclosed within the nanoparticle containing are described. Also provided are methods for treating or preventing diseases or conditions in a subject by administering the nanoparticle compositions that provide immune responses and synergistic therapeutic or preventive effects.
Core Innovation
The invention concerns a compound of Formula I and aminoalkyl branched lipid-like compounds for use as carriers for nucleic acid delivery. The compounds are defined by variable substituent groups YA, ZA, ZB, ZC, ZD, LK1, LK2, LK3, and LK4, and the compound has 40 to 100 carbon atoms. The disclosed subject matter defines the aminoalkyl branched lipid-like architecture through these structural constraints.
The disclosure further relates to nanoparticle compositions that comprise the described compound, PEG-lipid, phospholipid, cholesterol or cholesterol derivatives, and a therapeutic or immunogenic nucleic acid agent. The nucleic acid agents include polynucleotide, oligonucleotide, DNA, cDNA, RNA, repRNA, siRNA, miRNA, sgRNA, and mRNA, and the compositions are described as fully or partially encapsulating a therapeutic or immunogenic nucleic acid.
The document includes nanoparticle examples and characterization by DLS, encapsulation efficiency, reporter expression assays including SEAP and luciferase, and in vivo biodistribution of luciferase mRNA nanoparticles in mice using imaging. It also includes treatment and delivery language for infectious disease, pathogen, cancer, autoimmunity disease, and allergenic disease contexts.
Claims Coverage
The independent claim set centers on two tracks: a Formula I aminoalkyl branched lipid-like compound with a 40 to 100 carbon-atom requirement, and nanoparticle compositions that include therapeutic or immunogenic nucleic acids with formulation constraints. In total, the consolidated claim coverage identifies five inventive features.
Formula I aminoalkyl branched lipid-like compound with 40 to 100 carbon atoms
A compound of Formula I in which YA is H or C1-C4 alkyl; ZA is C1-C30 amino, C1-C30 amido, C1-C30 carbonyl, C1-C30 carboxylate, or triazolyl; ZB is such that each of LC or LD is O; ZC is ZC2-XC-XC-ZC3 with XC as S, ZC2 as C4-C10 alkylene, and ZC3 as C6-C12 alkyl or alkenyl; ZD is C4-C10 alkylene substituted with C6-C12 disulfanyl; LK1 is bond or C3-C8 alkylene; LK2 is a bond or C1-C8 alkylene; each of LK3 and LK4 is —(CH2)2—; and the compound has 40 to 100 carbon atoms.
Nanoparticle composition for therapeutic or immunogenic nucleic acids
A nanoparticle composition that comprises a nucleic-acid carrier and a therapeutic or immunogenic nucleic acid agent selected from polynucleotides, oligonucleotides, DNA, cDNA, RNA, repRNA, siRNA, miRNA, sgRNA, and mRNA.
PEG-lipid loading range in nanoparticle composition
The nanoparticle composition comprises a PEG-lipid at a concentration ranging from 0.1 mol% to 10 mol% per nanoparticle composition.
Specified PEG-lipid identity
The nanoparticle composition comprises PEG-lipid selected from 1,2-dimyristoyl-sn-glycero-3-phosphoethanolamine-N-[methoxy (polyethylene glycol)-2000] or 1,2-dimyristoyl-rac-glycero-3-methoxypolyethylene glycol-2000.
Carrier molecules with variable ring, linker, and substituent definitions
Carrier molecules are defined by variables including Z1, Z2, X1, X2, B, and A, together with substituent and linker classes and polymerization length parameters l, m, and n having values from 0 to 20.
The claim coverage concentrates on a parameterized Formula I aminoalkyl branched lipid-like compound with a required 40 to 100 carbon atoms and on nanoparticle compositions for delivering therapeutic or immunogenic nucleic acids. The nanoparticle features include the specified nucleic acid classes, PEG-lipid loading, specified PEG-lipid identity, and additional carrier-variable definitions.
Stated Advantages
Biodegradability.
Improved delivery/payload release.
Improved expression for the disulfide-bond carrier versus non-disulfide in vivo.
Documented Applications
Carrier and nanoparticle-based packaging and delivery of therapeutic or immunogenic nucleic acids using aminoalkyl branched lipid-like compounds of Formula I.
Delivery of therapeutic or immunogenic nucleic acids for treatment in infectious disease, pathogen, cancer, autoimmunity disease, and allergenic disease contexts.
Delivering therapeutic or immunogenic nucleic acids using lipid nanoparticles, including antisense, siRNA, miRNA, and gene targeting/genome editing via CRISPR system elements, meganucleases, TALEN, and zinc finger nucleases (ZFNs).
In vivo reporter expression and biodistribution studies using luciferase mRNA nanoparticles in mice, including imaging-based biodistribution measurements.
In vitro reporter expression measurements using SEAP assays and related readouts.
In vivo BALB/c mouse SEAP expression evaluation using nanoparticle compositions containing RNA carriers of Formula 1f/1f-like compounds, comparing disulfide-bond-containing carrier and non-disulfide-bond-containing carrier.
Interested in licensing this patent?